CMOPF News Today: Stay Updated with the Latest Cosmo Pharmaceuticals N.V. News in Real Time
Find CMOPF news now at Meyka AI. Stay informed with the latest{" "} Cosmo Pharmaceuticals N.V. stocks updates, including price news, market analysis, and expert insights.
Nifty 50 EPS Cuts: Cipla, L&T, Adani Enterprises & Adani Ports Among 31 Downgraded Stocks in FY27 Forecast
Earnings expectations for India’s top companies are facing fresh pressure. In May 2026, analysts lowered FY27 earnings-per-share (EPS) forecasts for 31 of the 50 companies in the Nifty 50 index, highlighting growing concerns about profit growth across key sectors. Major names such as Cipla, L&T, Adani Enterprises, and Adani Ports were among those affected. The…
US Proposes 12.5% Tariff on Singapore Over Forced Labour Rules, June 04
US Trade Representative proposes 12.5% tariff on Singapore over forced labour enforcement failures, affecting 60 countries and 99% of US imports.
Hang Seng Index Eyes 28,000 as Analysts Favor AI and Healthcare
Everbright Securities targets Hang Seng Index at 28,000 points in H2 2026, favoring AI, healthcare, and consumer stocks amid China’s policy support.
Switzerland-Egypt Trade May 26: $2.3B Partnership Strengthens
Switzerland-Egypt trade reached $2.3B in 2025. Swiss investment ranks top 10 in Egypt with growing bilateral partnership opportunities.
Tsuruhа Drugstore May 24: Japan’s Retail Consolidation Boom
Tsuruha’s expansion reshapes Japan’s drugstore landscape through digital innovation and retail consolidation strategies.
India-Nordic Summit May 24: Modi Strengthens Trade Ties
India-Nordic summit in Oslo on May 24 strengthens strategic ties and boosts trade partnerships with Norway, Sweden, Finland, Iceland, and Denmark.
SNOA Director Jacoby Vanessa Stock Option Filing, May 22, 2026
Sonoma Pharmaceuticals director Jacoby Vanessa files initial stock option ownership of 10,000 shares valued at $100M on February 9, 2026.
CASIF Stock: Wang Chunhua COO Option Filing May 22, 2026
CASI Pharmaceuticals COO Wang Chunhua files initial ownership of 7,500 stock options valued at $20,025. SEC Form 3 filing details.
Sun Pharmaceutical (SUNPHARMA.NS) Earnings Preview: EPS at $11.34 Expected
SUNPHARMA.NS earnings preview: EPS estimate $11.34, revenue $145.57B. Analyst expectations ahead of May 22, 2026 report.